
Join Dr. Kim as he explores the pathogenesis of CSU and the mechanisms that promote itch in CSU. The complex interplay of type 2 inflammation in CSU is examined, offering insights into its unique challenges for patients and clinicians alike.

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

Join Dr. Brian Kim in discussing the diagnosis of CPUO and the role of type 2 inflammation in disease pathophysiology.

Learn about key drivers of type 2 inflammation in EoE and how they mediate progressive esophageal remodeling and impact patient burden

In this final video, Dr. Kim compares the shared and distinct pathophysiological features that drive itch in AD, PN, and CSU. He ties together the knowledge from earlier episodes, highlighting the similarities and differences in the mechanisms of itch across these diseases.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.
Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.
At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.